128 related articles for article (PubMed ID: 38615670)
21. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
22.
Zhuang Q; Chen Z; Shen J; Fan M; Xue D; Lu H; Xu R; He X
Onco Targets Ther; 2019; 12():119-134. PubMed ID: 30588036
[TBL] [Abstract][Full Text] [Related]
23. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
[TBL] [Abstract][Full Text] [Related]
24. Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis.
Wang HL; Zhou PY; Liu P; Zhang Y
Mol Biol Rep; 2014 Jul; 41(7):4481-92. PubMed ID: 24610350
[TBL] [Abstract][Full Text] [Related]
25. Distinct promotor methylation at tumor suppressive genes in ovarian cancer stromal progenitor cells and ovarian cancer and its clinical implication.
Ho CM; Yen TL; Chien TY; Huang SH
Am J Cancer Res; 2022; 12(11):5325-5341. PubMed ID: 36504889
[TBL] [Abstract][Full Text] [Related]
26. Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis.
Wang H; Cui M; Zhang S; He J; Song L; Chen Y
Gynecol Obstet Invest; 2018; 83(4):349-357. PubMed ID: 29130987
[TBL] [Abstract][Full Text] [Related]
27. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
29. Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA.
Millares L; Serra M; Andreo F; Sanz-Santos J; Montón C; Grimau C; Gallego M; Setó L; Combalia N; Llatjos M; Escoda R; Castellà E; Monsó E
Clin Exp Metastasis; 2015 Oct; 32(7):637-46. PubMed ID: 26119430
[TBL] [Abstract][Full Text] [Related]
30. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A
Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521
[TBL] [Abstract][Full Text] [Related]
31. Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.
Jiang JL; Tian GL; Chen SJ; Xu LI; Wang HQ
Exp Ther Med; 2015 Oct; 10(4):1549-1555. PubMed ID: 26622524
[TBL] [Abstract][Full Text] [Related]
32. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
33. Quantitative assessment of aberrant
Ruan J; Xu P; Fan W; Deng Q; Yu M
Cancer Manag Res; 2018; 10():3033-3046. PubMed ID: 30214298
[TBL] [Abstract][Full Text] [Related]
34. RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.
Shou F; Xu F; Li G; Zhao Z; Mao Y; Yang F; Wang H; Guo H
Onco Targets Ther; 2017; 10():247-257. PubMed ID: 28123306
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
[TBL] [Abstract][Full Text] [Related]
36. Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.
Guo Y; Long J; Lei S
J Cell Physiol; 2019 May; 234(5):7356-7367. PubMed ID: 30370527
[TBL] [Abstract][Full Text] [Related]
37. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
38. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
Wei H; Fang N; Guo L; Wu Z; Zhou Q
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
[TBL] [Abstract][Full Text] [Related]
39. BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
Ignatov T; Eggemann H; Costa SD; Roessner A; Kalinski T; Ignatov A
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1457-63. PubMed ID: 24825122
[TBL] [Abstract][Full Text] [Related]
40. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
Si JG; Su YY; Han YH; Chen RH
Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]